As discoveries of novel retinal imaging technologies continue to emerge into the space, ophthalmic drug developers must assess their potential to be adopted for preclinical and clinical assessments of disease activity and patient response
In this session, you will:
- Learn how to navigate the crowded space to define good and bad imaging biomarkers for retinal therapeutic development
- Evaluate the translatability of novel imaging modalities emerging from academic research and their ability to produce clinically useful outcomes
Workshop leaders:
Khaled Nassar, Principal Expert Retinal Health, Principal Clinical Biomarker Lead, Boehringer Ingelheim
Stephen Poor, Clinical Development Ophthalmology & Global Drug Development, Medical Lead Ophthalmology, Novartis
David Callanan, Chief Medical Officer, Aviceda Therapeutics
Ramkumar Ramamirtham, Associate Director & Optometrist, Novartis
Brijesh Yadav, Clinical & Translational Imaging Principal Scientist, Novartis